WS
Therapeutic Areas
Retension Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RTN-001 | Uncontrolled Hypertension | Phase 2 |
Leadership Team at Retension Pharmaceuticals
EK
Eric Keller
Chief Executive Officer, Founder & Chairman
PS
Paul Sweetnam
Chief Scientific Officer & Co-Founder